Will Garner

1.3k citations

30 papers · 772 indexed · 1 hit paper · h-index 12

Impact in

Virology top 2%
- HIV Research and Treatment
Infectious Diseases top 5%
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions

Papers in ⓘ

Virology 14
- HIV Research and Treatment 14
Infectious Diseases 18
- HIV/AIDS drug development and treatment 17
- HIV/AIDS Research and Interventions 8

Co-authors: Anton Pozniak (4 shared papers)Kirsten White (5 shared papers)Erin Quirk (3 shared papers)Andrew Cheng (2 shared papers)Andrea Antinori (4 shared papers)Hans-Jürgen Stellbrink (2 shared papers)Joseph M. Custodio (1 shared paper)Devi SenGupta (1 shared paper)
Journals: Journal of the International AIDS Society (3 papers)Journal of Hepatology (3 papers)AIDS (3 papers)Patient (3 papers)The Lancet (2 papers)
Partner nations: United States United Kingdom Germany

In The Last Decade

Will Garner

27 papers receiving 761 citations

Hit Papers

align trajectories log scale

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial 2017 · 278 citations

Peers

Countries citing papers authored by Will Garner

Since Specialization

Citations

This map shows the geographic impact of Will Garner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Will Garner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Will Garner more than expected).

Fields of papers citing papers by Will Garner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Will Garner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Will Garner. The network helps show where Will Garner may publish in the future.

Co-authors

The 25 scholars most cited alongside Will Garner, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Will Garner Line = papers co-authored together Will Garner links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial The Lancet ·Paul E. Sax, Anton Pozniak, Marisa Montes, Ellen Koenig, Edwin DeJesus, Hans-Jürgen Stellbrink, Andrea Antinori, Kimberly Workowski, Jihad Slim, Jacques Reynes, Will Garner, Joseph M. Custodio, Kirsten White, Devi SenGupta, Andrew Cheng, Erin Quirk Hit paper breakdown →	2017	278
2	Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study The Lancet ·Emmanuel Gonzalès, Winita Hardikar, Michael Stormon, Alastair Baker, Loreto Hierro, Dorota Gliwicz, Florence Lacaille, Alain Lachaux, Ekkehard Sturm, Kenneth D.R. Setchell, Ciara Kennedy, Alejandro Dorenbaum, Jana I. Steinmetz, Nirav K. Desai, Andrew J Wardle, Will Garner, Pamela Vig, Thomas Jaecklin, Étienne Sokal, Emmanuel Jacquemin	2021	103
3	Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trial The Lancet Infectious Diseases ·Anton Pozniak, Martin Markowitz, Anthony Mills, Hans‐Juergen Stellbrink, Antonio Antela, Peré Domingo, Pierre‐Marie Girard, Keith Henry, Thai Nguyen, David Piontkowsky, Will Garner, Kirsten White, Bill Guyer	2014	75
4	Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies HIV Clinical Trials ·Mark Nelson, Richard Elion, C Cohen, Anthony Mills, Sally Hodder, Sorana Segal‐Maurer, Mark Bloch, Will Garner, Bill Guyer, Scott Williams, S.K. Chuck, Simon Vanveggel, H. Deckx, Marita Stevens	2013	46
5	Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B–Coinfected Adults JAIDS Journal of Acquired Immune Deficiency Syndromes ·Joel E. Gallant, Jason Brunetta, Gordon Crofoot, Paul Benson, Anthony Mills, Cynthia Brinson, Shinichi Oka, Andrew Cheng, Will Garner, Marshall W. Fordyce, Moupali Das, Scott McCallister, (unknown)	2016	44
6	Patient-Reported Symptoms Over 48 Weeks Among Participants in Randomized, Double-Blind, Phase III Non-inferiority Trials of Adults with HIV on Co-formulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide versus Co-formulated Abacavir, Dolutegravir, and Lamivudine Patient ·David A. Wohl, Amanda Clarke, Franco Maggiolo, Will Garner, Marianne Laouri, Hal Martin, Erin Quirk	2018	41
7	Maralixibat for the treatment of PFIC: Long‐term, IBAT inhibition in an open‐label, Phase 2 study Hepatology Communications ·Kathleen M. Loomes, Robert H. Squires, Déirdre Kelly, Sanjay Rajwal, Nisreen Soufi, Alain Lachaux, Irena Jankowska, Cara L. Mack, Kenneth D.R. Setchell, Palaniswamy Karthikeyan, Ciara Kennedy, Alejandro Dorenbaum, Nirav K. Desai, Will Garner, Thomas Jaecklin, Pamela Vig, Alexander Miethke, Richard J. Thompson	2022	39
8	Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults AIDS ·Jan van Lunzen, Andrea Antinori, Calvin Cohen, José Ramón Arribas, David A. Wohl, Armin Rieger, Anita Rachlis, Mark Bloch, Sorana Segal‐Maurer, Will Garner, Danielle Porter, Matthew Bosse, David Piontkowsky, Susan K. Chuck, Shampa De-Oertel	2015	27
9	Inhibition of DNA polymerases from RNA tumor viruses by tilorone and congeners: Site of action Biochemical Pharmacology ·Chandra Prakash, Will Garner, D. Gericke, A. Götz	1974	19
10	Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment AIDS Care ·Ed L. Wilkins, Calvin Cohen, Benoît Trottier, Stefan Eßer, Don Smith, Bernhard Haas, Cynthia Brinson, Will Garner, Susan K. Chuck, David Thorpe, Shampa De-Oertel	2015	17
11	Maralixibat Treatment Response in Alagille Syndrome is Associated with Improved Health-Related Quality of Life The Journal of Pediatrics ·Binita M. Kamath, Andrea Goldstein, Robin Howard, Will Garner, Pamela Vig, Jessica R. Marden, Emma Billmyer, Annika Anderson, Noam Y. Kirson, Emmanuel Jacquemin, Emmanuel Gonzalès	2022	15
12	Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Reverse Transcriptase Inhibitor with Emtricitabine and Tenofovir DF Patient ·Anthony Mills, Will Garner, Anton Pozniak, Juan Berenguer, Rebecca M. Speck, Randall H. Bender, Thai Nguyen	2015	11
13	Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Protease Inhibitor with Emtricitabine and Tenofovir DF Patient ·Joseph Gathe, José Ramón Arribas, Jan van Lunzen, Will Garner, Rebecca M. Speck, Randall H. Bender, Sanatan Shreay, Thai Nguyen	2015	11
14	Predictors of 6-year event-free survival in Alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor Hepatology ·Ronald J. Sokol, Emmanuel Gonzalès, Binita M. Kamath, Alastair Baker, Pamela Vig, Douglas Mogul, Will Garner, Bettina E. Hansen, Emmanuel Jacquemin, Richard J. Thompson	2023	8
15	Randomized study evaluating the efficacy and safety of switching from an an abacavir/lamivudine-based regimen to an elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen AIDS ·Giuliano Rizzardini, Andrea Gori, Celia Miralles, Julián Olalla, Jean‐Michel Molina, François Raffi, Princy Kumar, Andrea Antinori, Moti Ramgopal, Hans-Jürgen Stellbrink, Moupali Das, Hoa Chu, Renee R. Ram, Will Garner, Yongwu Shao, Susan K. Chuck, David Piontkowsky, Richard Haubrich	2019	6
16	Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY‐NNRTI subgroup analysis Journal of the International AIDS Society ·Hans‐Juergen Stellbrink, Andrea Antinori, Anton Pozniak, Jason Flamm, Fritz Bredeek, Kiran Patel, Will Garner, David Piontkowsky	2014	6
17	A Double-Blind, Multicentre, Randomised, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome®) for the Prevention of Invasive Fungal Infections in Subjects Receiving Remission-Induction Chemotherapy for Acute Lymphoblastic Leukaemia (AmBiGuard trial) Blood ·Oliver A. Cornely, Thibaut Leguay, Johan Maertens, Carlo Castagnola, Αchilles Anagnostopoulos, Bernadino Allione, Claus Peter Heußel, J. Peter Donnelly, Samir Agrawal, Will Garner, Catherine Simcock, Michael Hawkins, Nicola Goekbuget	2014	6
18	Colchicine for Familial Mediterranean Fever (Periodic Peritonitis) — Concl. New England Journal of Medicine ·Will Garner	1974	5
19	Simplification to Stribild vs continuation of RTV‐boosted DRV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY‐PI subgroup analysis Journal of the International AIDS Society ·José Ramón Arribas, Giuliano Rizzardini, Keikawus Arastéh, Christine Zurawski, Craig Dietz, Dennis Pontani, Will Garner, Thai Nguyen	2014	3
20	Maralixibat leads to significant reductions in pruritus and improvements in sleep for children with progressive familial intrahepatic cholestasis: data from MARCH-PFIC Journal of Hepatology ·Richard Thompson, Douglas Mogul, Tiago Nunes, Will Garner, Pamela Vig, Alexander Miethke	2023	3

About Will Garner

Will Garner is a scholar working on Virology, Infectious Diseases, Hepatology, Emergency Medicine and Oncology, having authored 30 papers that have together received 772 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (17 papers), HIV Research and Treatment (14 papers), HIV/AIDS Research and Interventions (8 papers), Pediatric Hepatobiliary Diseases and Treatments (7 papers), Drug Transport and Resistance Mechanisms (5 papers), HIV-related health complications and treatments (4 papers), Liver Diseases and Immunity (4 papers) and Gallbladder and Bile Duct Disorders (3 papers). The work is most often cited by research in Virology (376 citations), Infectious Diseases (543 citations), Emergency Medicine (209 citations), Hepatology (137 citations) and Oncology (118 citations). Will Garner has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Anton Pozniak, Kirsten White, Erin Quirk, Andrew Cheng, Andrea Antinori, Hans-Jürgen Stellbrink, Joseph M. Custodio, Devi SenGupta, Marisa Montes and Ellen Koenig. Their work appears in journals such as Journal of the International AIDS Society, Journal of Hepatology, AIDS, Patient and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact